Diabetes Type 2 Drugs May Lead to Cancer

Diabetes is one of the most life-threatening diseases in the whole world. According to WHO, 347 million people, worldwide, have diabetes. The leading organization also predicts that by 2030, diabetes will be the 7^th leading cause of deaths. The two types of diabetes vary in some characteristics but the damage to the body is similar. The term “diabetes mellitus” describes a metabolic disorder of multiple aetiology characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both”.

A new research has proven that a drug used to treat the patients of the Type 2 diabetes, may lead to increased risk of bladder cancer. Type 2 diabetes (formerly called non-insulin-dependent or adult-onset) results from the body’s ineffective use of insulin. Type 2 diabetes comprises 90% of people with diabetes around the world, and is largely the result of excess body weight and physical inactivity. This recent research may increase the rate of death among diabetic patients due to drug induced bladder cancer. The researchers have conducted a systematic review and meta-analysis to determine the chances of bladder cancer in adults suffering from type 2 diabetes mellitus using thiazolidinediones. They suggested that type 2 diabetic patients have 40% more chances of development of cancer.

This study is very helpful for physicians who are specialist in diabetes management and treatment. It would be very healthy for patients if they are not prescribed pioglitazone rather there are various other Antidiabetic drugs that could be prescribed and they do not have any carcinogenic effect.

Bentham Science Publishers is one of the leading journals in the STM industry. It has journals and eBooks pertaining to topics from science, medicine, technology and the like. One of the journals is Endocrine, Metabolic & Immune Disorders - Drug Targets. This journal is devoted to timely reviews of experimental and clinical studies in the field of endocrine, metabolic, and immune disorders. Specific emphasis is placed on humoral and cellular targets for natural, synthetic, and genetically engineered drugs that enhance or impair endocrine, metabolic, and immune parameters and functions. Topics related to the neuroendocrine-immune axis are given special emphasis in view of the growing interest in stress-related, inflammatory, autoimmune, and degenerative disorders. Original articles related to Immune Disorders and Drug Targeting are also considered for publication.